Aurinia Pharmaceuticals Inc
AUPH11.350USD
+0.090+0.80%
收盤 10/03, 16:00（美東）報價延遲15分鐘
1.51B總市值
24.83本益比TTM
關於 Aurinia Pharmaceuticals Inc 公司
Aurinia Pharmaceuticals Inc. 是一家完全整合的生物製藥公司。該公司專注於爲患有自身免疫性疾病且醫療需求尚未得到滿足的患者提供治療。該公司已開發出 LUPKYNIS（voclosporin），這是一種用於治療活動性狼瘡性腎炎 (LN) 成人患者的口服療法，並繼續開展臨牀和監管活動以支持 LUPKYNIS 開發計劃。該公司主要致力於開發其管線資產 AUR200，這是一種針對 BAFF（B 細胞活化因子）和 APRIL（增殖誘導配體）的差異化、潛在的下一代自身免疫性疾病療法。該公司與大塚製藥株式會社 (Otsuka) 簽訂了合同，作爲合作伙伴在大塚地區開發和商業化 LUPKYNIS。該公司主要向專科藥房和專科分銷商以及其美國以外的合作伙伴大塚銷售 LUPKYNIS（voclosporin）。
Aurinia Pharmaceuticals Inc簡介
公司代碼AUPH
公司名稱Aurinia Pharmaceuticals Inc
上市日期Jul 16, 2001
CEOMr. Peter S. Greenleaf
員工數量130
證券類型Ordinary Share
年結日Jul 16
公司地址#140, 14315 - 118 Avenue
城市EDMONTON
上市交易所NASDAQ Global Market Consolidated
國家Canada
郵編T5L 4S6
電話12507442487
網址https://www.auriniapharma.com
公司代碼AUPH
上市日期Jul 16, 2001
CEOMr. Peter S. Greenleaf
Aurinia Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
收入明細
單位: USD更新時間: 10月2日 週四
單位: USD更新時間: 10月2日 週四
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月17日 週日
更新時間: 8月17日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Tang Capital Management, LLC
7.62%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.91%
New Enterprise Associates (NEA)
3.02%
State Street Global Advisors (US)
2.12%
其他
77.37%
持股股東
持股股東
佔比
Tang Capital Management, LLC
7.62%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.91%
New Enterprise Associates (NEA)
3.02%
State Street Global Advisors (US)
2.12%
其他
77.37%
股東類型
持股股東
佔比
Investment Advisor
13.16%
Hedge Fund
12.86%
Investment Advisor/Hedge Fund
12.24%
Corporation
4.96%
Venture Capital
3.02%
Research Firm
2.52%
Individual Investor
2.49%
Pension Fund
0.74%
Bank and Trust
0.31%
其他
47.69%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
429
59.45M
45.16%
-10.76M
2025Q2
446
77.42M
58.75%
-1.04M
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Tang Capital Management, LLC
10.03M
7.62%
--
--
Jun 30, 2025
ILJIN SNT Co., Ltd.
6.54M
4.96%
-984.75K
-13.10%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
4.91%
-1.01M
-13.48%
Jun 30, 2025
New Enterprise Associates (NEA)
3.97M
3.02%
--
--
Jun 30, 2025
State Street Global Advisors (US)
2.80M
2.12%
-56.08K
-1.97%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.70M
1.29%
-36.55K
-2.10%
Jun 30, 2025
The Vanguard Group, Inc.
1.69M
1.29%
-250.93K
-12.90%
Jun 30, 2025
Armistice Capital LLC
1.63M
1.24%
-3.37M
-67.41%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.58M
1.2%
-157.24K
-9.07%
Jun 30, 2025
Qube Research & Technologies Ltd
1.24M
0.94%
+386.36K
+45.13%
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月2日 週四
更新時間: 10月2日 週四
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
2.43%
Janus Henderson Small Cap Growth Alpha ETF
2.01%
ALPS Medical Breakthroughs ETF
0.95%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.2%
SPDR S&P International Small Cap ETF
0.19%
Vanguard US Multifactor ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
Avantis US Small Cap Equity ETF
0.14%
iShares Biotechnology ETF
0.14%
查看更多
Virtus LifeSci Biotech Products ETF
佔比2.43%
Janus Henderson Small Cap Growth Alpha ETF
佔比2.01%
ALPS Medical Breakthroughs ETF
佔比0.95%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
佔比0.2%
SPDR S&P International Small Cap ETF
佔比0.19%
Vanguard US Multifactor ETF
佔比0.18%
ProShares Ultra Nasdaq Biotechnology
佔比0.17%
Invesco Nasdaq Biotechnology ETF
佔比0.16%
Avantis US Small Cap Equity ETF
佔比0.14%
iShares Biotechnology ETF
佔比0.14%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
